Physician profile
Erick A Mafong
NPI 1033113725
$5,558.66
in general payments reported to CMS, 2019-2025
32 companies · $1,387 in 2025
The $1,387 reported for 2025 was more than what 81% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $579 · 2020: $512 · 2021: $842 · 2022: $567 · 2023: $797 · 2024: $875 · 2025: $1,387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,689 · Education: $370.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,688.94 |
| Education | $369.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,032.29 | 2019-2025 | Tremfya |
| Abbvie INC. | $941.92 | 2019-2025 | |
| Pfizer INC. | $518.97 | 2019-2025 | |
| Ucb, INC. | $366.61 | 2020-2025 | Bimzelx |
| Amgen INC. | $349.53 | 2019-2024 | Otezla |
| Biofrontera INC. | $324.41 | 2019-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Regeneron Healthcare Solutions, INC. | $277.51 | 2021-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $240.49 | 2019-2025 | |
| Incyte Corporation | $232.18 | 2021-2025 | Opzelura |
| Vyne Pharmaceuticals INC. | $166.81 | 2020-2021 | |
| Organogenesis INC. | $151.36 | 2023-2025 | Via Matrix, Puraply, Puraply Wound Matrix |
| Novartis Pharmaceuticals Corporation | $86.05 | 2019-2025 | |
| Lilly USA, LLC | $81.78 | 2020-2022 | |
| Leo Pharma INC. | $79.37 | 2022-2025 | Adbry |
| Misonix INC | $79.28 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $78.09 | 2021-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $77.38 | 2019-2021 | |
| Strata Skin Sciences, INC. | $69.06 | 2024-2025 | Xtrac |
| Organon LLC | $52.58 | 2025 | Vtama |
| Genzyme Corporation | $43.66 | 2019-2021 | |
| Dermira, INC. | $41.36 | 2020-2021 | |
| Dermavant Sciences, INC. | $38.38 | 2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $37.80 | 2024 | Sotyktu |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.35 | 2025 | Spevigo |
| Verrica Pharmaceuticals INC. | $27.14 | 2024 | Ycanth |
| Galderma Laboratories, L.P. | $27.09 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $24.30 | 2021 | |
| Dusa Pharmaceuticals, INC. | $22.44 | 2019 | |
| Arcutis Biotherapeutics, INC. | $19.81 | 2025 | Zoryve |
| Helsinn Therapeutics (U.S.), INC. | $16.43 | 2025 | Valchlor |
| Bioventus LLC | $11.94 | 2022 | |
| Prugen, INC. Pharmaceuticals | $11.29 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erick Mafong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.